TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers

Epigenetics

Volumn 6, Issue 9, 2011, Pages 1120-1130

  Costa, Vera L ^a,b,c   Henrique, Rui ^a   Danielsen, Stine A ^b,c   Eknaes, Mette ^b,c   Patrício, Patrícia ^a   Morais, António ^a   Oliveira, Jorge ^a   Lothe, Ragnhild A ^b,d   Teixeira, Manuel R ^a   Lind, Guro E ^b,c   Jerónimo, Carmen ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Detection; DNA methylation; Urine test; Urological cancer

Indexed keywords

CADHERIN; PROTOCADHERIN 17; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 21; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER SCREENING; CANCER TISSUE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; URINALYSIS; VALIDITY;

EID: 80052585520     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.6.9.16376     Document Type: Article

References (36)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010; 60:277-300.
3. Veltri RW, Makarov DV Nucleic acid-based marker approaches to urologic cancers. Urol Oncol 2006; 24:510-27.
4. Cairns P. Gene methylation and early detection of genitourinary cancer: the road ahead. Nat Rev Cancer 2007; 7:531-43.
5. Scelo G, Brennan P. The epidemiology of bladder and kidney cancer. Nat Clin Pract Urol 2007; 4:205-17.
6. Henrique R, Costa VL, Jeronimo C. Methylation-based biomarkers for early detection of urological cancer. Crit Rev Oncog 2007; 13:265-82.
7. Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 2006; 98:996-1004.
8. Aleman A, Adrien L, Lopez-Serra L, Cordon-Cardo C, Esteller M, Belbin TJ, et al. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br J Cancer 2008; 98:466-73.
9. Renard I, Joniau S, van Cleynenbreugel B, Collette C, Naome C, Vlassenbroeck I, et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur Urol 2010; 58:96-104.
10. Hoque MO, Begum S, Topaloglu O, Jeronimo C, Mambo E, Westra WH, et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine and serum DNA of patients with renal cancer. Cancer Res 2004; 64:5511-7.
11. Costa VL, Henrique R, Ribeiro FR, Pinto M, Oliveira J, Lobo F, et al. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer 2007; 7:133.
12. Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, Brown M, et al. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 2010; 29:2104-17.
13. Vener T, Derecho C, Baden J, Wang H, Rajpurohit Y, Skelton J, et al. Development of a multiplexed urine assay for prostate cancer diagnosis. Clin Chem 2008; 54:874-82.
14. Payne SR, Serth J, Schostak M, Kamradt J, Strauss A, Thelen P, et al. DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection. Prostate 2009; 69:1257-69.
15. Troyer DA, Lucia MS, de Bruine AP, Mendez-Meza R, Baldewijns MM, Dunscomb N, et al. Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies. Cancer Epidemiol Biomarkers Prev 2009; 18:2717-22.
16. Jeronimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson WG, et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 2001; 93:1747-52.
17. Jeronimo C, Usadel H, Henrique R, Silva C, Oliveira J, Lopes C, et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 2002; 60:1131-5.
18. Costa VL, Henrique R, Danielsen SA, Duarte-Pereira S, Eknaes M, Skotheim RI, et al. Three epigenetic biomarkers, GDF15, TMEFF2 and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res 2010; 16:5842-51.
19. Lind GE, Kleivi K, Meling GI, Teixeira MR, Thiis-Evensen E, Rognum TO, et al. ADAMTS1, CRABP1 and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol 2006; 28:259-72.
20. Lind GE, Ahlquist T, Kolberg M, Berg M, Eknaes M, Alonso MA, et al. Hypermethylated MAL gene-a silent marker of early colon tumorigenesis. J Transl Med 2008; 6:13.
21. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21:103-7.
22. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310-9.
23. Troyer DA, Mubiru J, Leach RJ, Naylor SL. Promise and challenge: Markers of prostate cancer detection, diagnosis and prognosis. Dis Markers 2004; 20:117-28.
24. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374:239-49.
25. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005; 23:202-12.
26. Lopez-Beltran A, Carrasco JC, Cheng L, Scarpelli M, Kirkali Z, Montironi R. 2009 update on the classification of renal epithelial tumors in adults. Int J Urol 2009; 16:432-43.
27. Veerla S, Panagopoulos I, Jin Y, Lindgren D, Hoglund M. Promoter analysis of epigenetically controlled genes in bladder cancer. Genes Chromosomes Cancer 2008; 47:368-78.
28. Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H, Sunderji A, et al. Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One 2009; 4:4830.
29. Morishita H, Yagi T Protocadherin family: diversity, structure, and function. Curr Opin Cell Biol 2007; 19:584-92.
30. Quaggin SE, Vanden Heuvel GB, Igarashi P. Pod-l, a mesoderm-specific basic-helix-loop-helix protein expressed in mesenchymal and glomerular epithelial cells in the developing kidney. Mech Dev 1998; 71:37-48.
31. Haruki S, Imoto I, Kozaki K, Matsui T, Kawachi H, Komatsu S, et al. Frequent silencing of protocadherin 17, a candidate tumour suppressor for esophageal squamous cell carcinoma. Carcinogenesis 2010; 31:1027-36.
32. Smith LT, Lin M, Brena RM, Lang JC, Schuller DE, Otterson GA, et al. Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. Proc Natl Acad Sci USA 2006; 103:982-7.
33. Tessema M, Willink R, Do K, Yu YY, Yu W, Machida EO, et al. Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-5. Cancer Res 2008; 68:1707-14.
34. Shivapurkar N, Stastny V, Xie Y, Prinsen C, Frenkel E, Czerniak B, et al. Differential methylation of a short CpG-rich sequence within exon 1 of TCF21 gene: a promising cancer biomarker assay. Cancer Epidemiol Biomarkers Prev 2008; 17:995-1000.
35. Anglim PP, Galler JS, Koss MN, Hagen JA, Turla S, Campan M, et al. Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. Mol Cancer 2008; 7:62.
36. Richards KL, Zhang B, Sun M, Dong W, Churchill J, Bachinski LL, et al. Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers. Cancer 2011; 117:606-17.